Conference Proceedings
Updated efficacy and safety results of the Bruton tyrosine kinase (BTK) degrader BGB-16673 in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) from the ongoing phase 1 CaDAnCe-101 study
Inhye Ahn, Ricardo Parrondo, Meghan Thompson, Annamaria Frustaci, John Allan, Paolo Ghia, Irina Mocanu, Damien Roos Weil, Constantine Tam, Stephan Stilgenbauer, Judith Trotman, Lydia Scarfo, Nicole Lamanna, Yanan Zhang, Linlin Xu, Kunthel By, Shannon Fabre, Daniel Persky, Amit Agarwal, John Seymour
Blood | American Society of Hematology | Published : 2025
Abstract
Introduction: BTK inhibitors are effective treatments for CLL/SLL; however, treatment intolerance and resistance to BTK inhibitors are major clinical challenges for many patients. BGB-16673 is an orally available protein degrader that blocks BTK signaling by tagging BTK for degradation through the cell's proteasome pathway, leading to tumor regression. CaDAnCe-101 (BGB-16673-101; NCT05006716) is an ongoing open-label, phase 1/2 study evaluating BGB-16673 monotherapy in patients with B-cell malignancies. Here, updated phase 1 safety and efficacy data are reported for patients with relapsed/refractory (R/R) CLL/SLL. Methods: Eligible patients must have confirmed R/R CLL/SLL (≥2 prior therapie..
View full abstract